Quick reference guide for health professionals

**Absolute cardiovascular disease risk management**

This quick reference guide is for use by health professionals for primary prevention of cardiovascular disease (CVD*). It provides a summary of the key steps involved in assessing and managing absolute cardiovascular disease risk. It is based on the Guidelines for the Management of Absolute Cardiovascular Disease Risk (2012) developed by the National Vascular Disease Prevention Alliance (NVDPA) and incorporates the previous Guidelines for the Assessment of Absolute Cardiovascular Disease Risk (2009). Patients with existing CVD are considered to be at high risk and should be managed with appropriate guidance for secondary prevention.

### Why use absolute risk?

Assessment of cardiovascular disease risk on the basis of the combined effect of multiple risk factors (absolute CVD risk) is more accurate than the use of individual risk factors, because the cumulative effects of multiple risk factors may be additive or synergistic. In Australia, 64% of the adult population have three or more modifiable risk factors. As CVD is largely preventable, an approach focusing on comprehensive risk assessment will enable effective management of identified modifiable risk factors through lifestyle changes and, where needed, pharmacological therapy.

### What does absolute risk mean?

Absolute risk is the numerical probability of a CVD event occurring within five years, expressed as a percentage. For example, if your patient’s risk is 15%, then you can tell them that 15 out of every 100 people are likely to have a CVD event within the next five years.

### What are the management goals?

Decisions regarding management of absolute CVD risk are made according to the individual’s absolute risk level. The management goal is to reduce the patient’s level of absolute risk. This is achieved by managing several individual risk factors, as the evidence shows that moderate reduction in several risk factors is more effective in reducing overall CVD risk than a major reduction in one factor.

### How do I monitor response to treatment?

Monitor your patient’s response to treatment by measuring their individual risk factors and adjusting medication or lifestyle advice accordingly.

### Grading of recommendations

For ease of use recommendations have been colour coded.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBR</td>
<td>Evidence-based recommendations.</td>
</tr>
<tr>
<td>CBR</td>
<td>Consensus-based recommendations; developed by the guidelines expert working group when a systematic review of the evidence found either an absence of direct evidence which answered the clinical question or poor quality evidence.</td>
</tr>
<tr>
<td>PP</td>
<td>Practice Point; practical guidance to support implementation.</td>
</tr>
</tbody>
</table>

---

* CVD refers collectively to coronary heart disease, stroke and other vascular disease including peripheral arterial disease and renovascular disease.

An initiative of the National Vascular Disease Prevention Alliance

The NVDPA is an alliance of four leading Australian charities: Diabetes Australia, Kidney Health Australia, the National Stroke Foundation and the National Heart Foundation of Australia. The NVDPA was established in 2000 to reduce cardiovascular disease in Australia.
Cardiovascular risk assessment tools provide a measure of a patient’s absolute cardiovascular risk. Use the algorithm and the charts on the next pages to calculate absolute risk.

**Target group for assessment**
- All adults aged 45 years and over without known history of CVD (EBR Grade B)
- Aboriginal and Torres Strait Islander peoples aged 35 years or older (EBR Grade D)

**Consider the following as part of a comprehensive risk assessment: (PP)**

**Modifiable risk factors**
- Smoking status
- Blood pressure
- Serum lipids
- Waist circumference and BMI
- Nutrition
- Physical activity level
- Alcohol intake

**Non-modifiable risk factors**
- Age and sex
- Family history of premature CVD
- Social history including cultural identity, ethnicity, socioeconomic status and mental health

**Related Conditions**
- Diabetes
- Chronic Kidney Disease (albuminuria ± urine protein, eGFR)
- Familial hypercholesterolaemia
- Evidence of atrial fibrillation (history, examination, electrocardiogram)

**Already known to be at increased risk?**

Adults with any of the following conditions do not require absolute CVD risk assessment using the Framingham Risk Equation (FRE) because they are already known to be at clinically determined high risk of CVD: (EBR Grade D)
- Diabetes and age >60 years
- Diabetes with microalbuminuria (>20 mcg/min or urinary albumin:creatinine ratio >2.5 mg/mmol for males, >3.5 mg/mmol for females)
- Moderate or severe CKD (persistent proteinuria or estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m²)
- A previous diagnosis of familial hypercholesterolaemia
- Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg
- Serum total cholesterol >7.5 mmol/L
- Aboriginal and Torres Strait Islander adults aged over 74 (CBR)

---

**Calculate risk level using FRE (EBR Grade B):**
- Australian cardiovascular risk charts
- Web calculator [www.cvdcheck.org.au](http://www.cvdcheck.org.au)
- Enter age 74 for adults aged 74+ (CBR)

**High:** greater than 15% risk of CVD within the next five years (includes clinically determined high risk) (PP)

**Moderate:** 10-15% risk of CVD within the next five years (PP)

**Low:** Less than 10% risk of CVD within the next five years (PP)
In accordance with Australian guidelines, patients with systolic blood pressure ≥180 mm Hg, or a total cholesterol of >7.5 mmol/L, should be considered at clinically determined high absolute risk of CVD.

Risk level for 5-year cardiovascular (CVD) risk

<table>
<thead>
<tr>
<th>High risk</th>
<th>Moderate risk</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30%</td>
<td>10–15%</td>
<td>≤5%</td>
</tr>
<tr>
<td>25–29%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20–24%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16–19%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

How to use the risk charts

1. Identify the chart relating to the person’s sex, diabetes status, smoking history and age. The charts should be used for all adults aged 45 years or over (and all Aboriginal and Torres Strait Islander adults aged 35 - 74 years) without known history of CVD and not already known to be at clinically determined high risk.

2. Within the chart choose the cell nearest to the person’s age, systolic blood pressure (SBP) and total cholesterol (TC):HDL ratio. For example, the lower left cell contains all non-smokers without diabetes who are 34-44 years and have a TC:HDL ratio of less than 4.5 and a SBP of less than 130 mmHg.

3. The colour of the cell that the person falls into provides their five year absolute cardiovascular risk level (see legend above for risk category). People who fall exactly on a threshold between cells are placed in the cell indicating higher risk.
In accordance with Australian guidelines, patients with systolic blood pressure ≥180 mm Hg, or a total cholesterol of >7.5 mmol/L, should be considered at clinically determined high absolute risk of CVD.

Risk level for 5-year cardiovascular (CVD) risk

- **High risk**
  - ≥30%
  - 25–29%
  - 20–24%
  - 16–19%

- **Moderate risk**
  - 10–15%

- **Low risk**
  - 5–9%
  - <5%

**Notes:** The risk charts include values for SBP alone as this is the most informative of conventionally measured blood pressure parameters for cardiovascular risk.

**For specific groups, additional guidance includes:**

- The Framingham Risk Equation may **underestimate CVD risk** in Aboriginal and Torres Strait Islander peoples (EBR Grade D); adults with diabetes aged between 45 and 60 years (EBR Grade C); adults aged over 74 years (CBR) however, available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk.

- The Framingham Risk Equation is likely to **underestimate CVD risk** in adults with socioeconomic deprivation (an independent risk factor for cardiovascular disease) (PP) or depression (PP).

- The predictive value of the Framingham Risk Equation **has not been specifically assessed** in adults who are overweight or obese (EBR Grade D).

- The **increased risk of cardiovascular events and all-cause mortality**, in addition to thromboembolic disease including stroke, should be taken into account for adults with atrial fibrillation (particularly those aged over 65 years) (PP).

### Risk management summary table

Use the table below to develop a management plan for your patients.

<table>
<thead>
<tr>
<th>CVD risk</th>
<th>Lifestyle</th>
<th>Pharmacotherapy</th>
<th>Targets</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HIGH RISK</strong></td>
<td>Frequent and sustained specific advice and support regarding diet and physical activity.</td>
<td>Treat simultaneously with lipid lowering and BP lowering unless contraindicated or clinically inappropriate.</td>
<td>BP: ≤140/90 mmHg in general or people with CKD; ≤130/80 mmHg in all people with diabetes; ≤130/80 mmHg if micro or macro albuminuria (UACR &gt; 2.5 mg/mmol in men and &gt;3.5 mg/mmol in women).</td>
<td>Review response 6-12 weekly until sufficient improvement or maximum tolerated dose achieved.</td>
</tr>
<tr>
<td>Clinically determined or calculated using FRE as &gt;15% absolute risk of CVD events over 5 years</td>
<td>Appropriate advice, support and pharmacotherapy for smoking cessation.</td>
<td>Aspirin not routinely recommended.</td>
<td></td>
<td>Adjust medication as required.</td>
</tr>
<tr>
<td>Advice given simultaneously with BP and lipid lowering drug treatment.</td>
<td>Consider withdrawal of therapy for people who make profound lifestyle changes.</td>
<td></td>
<td></td>
<td>Review of absolute risk according to clinical context.</td>
</tr>
<tr>
<td><strong>MODERATE RISK</strong></td>
<td>Appropriate, specific advice and support regarding diet and physical activity.</td>
<td>Not routinely recommended.</td>
<td>Lipids: TC &lt;4.0 mmol/L; HDL-C ≥1.0 mmol/L; LDL-C &lt;2.0 mmol/L; Non HDL-C &lt;2.5 mmol/L; TG &lt;2.0 mmol/L.</td>
<td>Review response 6-12 weekly until sufficient improvement or maximum tolerated dose achieved.</td>
</tr>
<tr>
<td>Calculated using FRE as 10-15% absolute risk of CVD events over 5 years</td>
<td>Appropriate advice, support and pharmacotherapy for smoking cessation.</td>
<td>Consider BP lowering and/or lipid lowering in addition to lifestyle advice if 3-6 months of lifestyle intervention does not reduce risk or:</td>
<td></td>
<td>Adjust medication as required.</td>
</tr>
<tr>
<td>Lifestyle advice given in preference to drug therapy.</td>
<td>• BP persistently ≥160/100 mmHg</td>
<td></td>
<td></td>
<td>Review absolute risk every 6-12 months.</td>
</tr>
<tr>
<td><strong>LOW RISK</strong></td>
<td>Brief, general lifestyle advice regarding diet and physical activity.</td>
<td>Not routinely recommended.</td>
<td></td>
<td>Review response 6-12 weekly until sufficient improvement or maximum tolerated dose achieved.</td>
</tr>
<tr>
<td>Calculated using FRE as &lt;10% absolute risk of CVD events over 5 years</td>
<td>Appropriate advice, support and pharmacotherapy for smoking cessation.</td>
<td>Consider BP lowering therapy in addition to specific lifestyle advice if BP persistently ≥160/100 mmHg.</td>
<td></td>
<td>Adjust medication as required.</td>
</tr>
<tr>
<td>Advice given simultaneously with BP and lipid lowering drug treatment.</td>
<td>Consider withdrawal of therapy for people who make profound lifestyle changes.</td>
<td></td>
<td></td>
<td>Review absolute risk every 2 years.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blood test results within 5 years can be used.</td>
</tr>
</tbody>
</table>

A&TSI: Aboriginal and Torres Strait Islander peoples; BP: blood pressure; CKD: Chronic Kidney Disease; CVD: cardiovascular disease; DBP: diastolic blood pressure; FRE: Framingham Risk Equation; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; SBP: systolic blood pressure; TC: total cholesterol; TG: Triglycerides; UACR: urinary albumin:creatinine ratio.
Lifestyle advice

People at all risk levels can make improvements to their health and reduce their risk of CVD by making lifestyle changes. The table below gives guidance on the basic lifestyle advice. For more detailed advice refer to the relevant guidelines.

<table>
<thead>
<tr>
<th>Lifestyle factor</th>
<th>Advice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diet</td>
<td>Consume a varied diet rich in vegetables, fruits, wholegrain cereals, lean meat, poultry, fish, eggs, nuts and seeds, legumes and beans, and low-fat dairy products. See Dietary Guidelines for all Australians.</td>
</tr>
<tr>
<td>Fats</td>
<td>Limit foods containing saturated and trans fats.</td>
</tr>
<tr>
<td>Salt</td>
<td>Limit salt to &lt;6g/day (approximately 2300 mg sodium).</td>
</tr>
<tr>
<td>Alcohol</td>
<td>Limit alcohol intake to ≤2 standard drinks per day. See Australian Guidelines to reduce health risks from drinking alcohol (2009).</td>
</tr>
<tr>
<td>Physical activity</td>
<td>At least 30 minutes moderate intensity physical activity on most or preferably every day of the week.</td>
</tr>
<tr>
<td>Weight</td>
<td>Limit energy intake to maintain a healthy weight. Ideal weight should be BMI &lt;25 kg/m² and waist circumference ≤94 cm in men (&lt;90 cm in Asian men) or ≤80 cm in women (including Asian women).³</td>
</tr>
<tr>
<td>Smoking</td>
<td>Stop smoking using counselling and, if required, nicotine replacement therapy or other medication.</td>
</tr>
</tbody>
</table>

** NHMRC Evidence-based recommendations:
- **Grade A**: Body of evidence can be trusted to guide practice
- **Grade B**: Body of evidence can be trusted to guide practice in most situations.
- **Grade C**: Body of evidence provides some support for recommendation(s) but care should be taken in its application.
- **Grade D**: Body of evidence is weak and recommendation must be applied with caution.
Blood pressure lowering therapy

In general

Consider treatable secondary causes of raised blood pressure before commencing drug therapy (PP)

In adults aged over 74 years, use clinical judgement to consider benefits and risks of treatment, co-morbidities and values before initiating therapy (PP)

Start drug therapy with any one of the following: (EBR Grade A)

- ACE inhibitor
- Angiotensin receptor blocker
- Calcium channel blocker
- Low-dose thiazide or thiazide-like diuretic

If monotherapy does not sufficiently reduce blood pressure add a second agent from a different class (EBR Grade A)

If dual therapy at higher doses does not sufficiently reduce blood pressure add a third agent (PP)

If blood pressure is not responding to pharmacotherapy, reassess for non-adherence; undiagnosed secondary causes for raised blood pressure; hypertensive effects of other drugs; treatment resistance due to sleep apnoea; undisclosed use of alcohol or recreational drugs; unrecognised high salt intake (particularly in patients taking ACE inhibitors or angiotensin receptor blockers); “white coat” raised blood pressure; technical factors affecting measurement; volume overload, especially with CKD (PP)

If combination therapy does not sufficiently reduce blood pressure, consider specialist advice (PP)

Avoid the following combinations: (PP)

- Potassium-sparing diuretic plus either ACE inhibitor or angiotensin receptor blocker
- Beta blocker plus verapamil

In those with diabetes

Blood pressure lowering therapy in people with diabetes should preferentially include one of the following: (EBR Grade A)

- ACE inhibitor
- Angiotensin receptor blocker

If monotherapy does not sufficiently reduce blood pressure add one of the following:

- Calcium channel blocker (EBR Grade B)
- Low-dose thiazide or thiazide-like diuretic (EBR Grade C)

In those with chronic kidney disease

Blood pressure lowering therapy in people with CKD should begin with one of the following: (EBR Grade A)

- ACE inhibitor
- Angiotensin receptor blocker
Lipid lowering therapy

In general

Consider treatable secondary causes of raised blood lipids before commencing drug therapy (PP)

In adults aged over 74 years, use clinical judgement to consider benefits and risks of treatment, co-morbidities and values before initiating therapy (PP)

Use statins as first line therapy (EBR Grade A)

If LDL-C levels are not sufficiently reduced on maximally tolerated doses of statin, add one or more of the following:

- Ezetimibe (EBR Grade C)
- Bile acid binding resin (EBR Grade D)
- Nicotinic acid (EBR Grade D)

For those intolerant to statins

Use one or more of the following:

- Ezetimibe (EBR Grade D)
- Bile acid binding resin (EBR Grade D)
- Nicotinic acid (EBR Grade D)

For raised triglycerides

Consider treatment with one of the following:

- Fenofibrate (especially if HDL is below target) (EBR Grade C)
- Nicotinic acid (EBR Grade C)
- Fish oil (EBR Grade C)

References


An initiative of the National Vascular Disease Prevention Alliance

Links to the full Guidelines for the Management of Absolute Cardiovascular Disease Risk can be found at:

www.diabetesaustralia.com.au
www.kidney.org.au
www.heartfoundation.org.au
www.strokefoundation.com.au
www.cvdcheck.org.au

Disclaimer: This document has been produced by the NVDPA for the information of health professionals. The statements and recommendations it contains are, unless labeled as ‘Consensus Based Recommendations’ or ‘Practice Points’, based on independent review of the available evidence. Interpretation of this document by those without appropriate medical and/or clinical training is not recommended, other than at the request of, or in consultation with, a relevant health professional. While care has been taken in preparing the content of this material, the NVDPA and their employees cannot accept any liability, including for any loss or damage, resulting from reliance on the content, or for its accuracy, currency and completeness. This material may be found in third parties’ programs or materials (including but not limited to show bags or advertising kits). This does not imply an endorsement or recommendation by the NVDPA for such third parties’ organisations, products or services, including these parties’ materials or information. Any use of NVDPA material by another person or organisation is done so at the user’s own risk. The entire contents of this material are subject to copyright protection.
